CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Option exercise Director acquired 11,041 shares (option exercise)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 6,018 shares at $38.48 ($231,546)
- 4 Planned sale CHIEF MEDICAL OFFICER sold 5,000 shares at $38.47 ($192,342)
- 144 Insider Sale of Securities
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Open-market sale Director sold 13,000 shares at $46.67 ($606,719)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 6,018 shares at an average $50.35 ($303,003)
- 4 Planned sale CHIEF MEDICAL OFFICER sold 5,000 shares at an average $50.35 ($251,754)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 6,018 shares at an average $58.58 ($352,551)
- 4 Planned sale CHIEF MEDICAL OFFICER sold 5,000 shares at an average $58.59 ($292,931)
- 4 Planned sale Director sold 158,795 shares at $60.21 ($9,561,587)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
Page 1 of 40 · 798 filings